Inotiv, Inc. (NOTV) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Inotiv, Inc. (NOTV) Healthcare & Pipeline Overview

Inotiv, Inc. delivers drug discovery and development solutions, alongside analytical instruments, to the pharmaceutical, chemical, and medical device sectors. Operating through Contract Research Services and Research Products segments, Inotiv supports preclinical and clinical studies with comprehensive testing and monitoring services, positioning itself as a key partner in the drug development lifecycle.

What Is the Investment Thesis for NOTV?

Inotiv, Inc. presents a compelling, albeit high-risk, investment thesis centered on its comprehensive suite of drug discovery and development services. The company's two-segment structure, encompassing Contract Research Services and Research Products, allows for diversified revenue streams. A key value driver is the increasing demand for preclinical research services, fueled by pharmaceutical and biotech companies' robust pipelines. Inotiv's agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program highlights its capabilities in supporting novel therapeutic development. However, with a market cap of $2.79M and a negative profit margin of -13.5%, the company faces significant financial challenges. The high beta of 4.08 indicates substantial volatility. Successful execution of strategic initiatives and a return to profitability are critical for realizing the company's potential. Upcoming catalysts include potential new partnerships and expansion of service offerings.

Based on FMP financials and quantitative analysis

NOTV Key Highlights

• Market Cap of $2.79M indicates a small-cap company with potential for high growth but also significant risk.
• Profit Margin of -13.5% reflects current challenges in achieving profitability, requiring close monitoring of cost management and revenue generation.
• Gross Margin of 18.1% suggests some pricing power and efficiency in service delivery, but there is room for improvement compared to industry benchmarks.
• Beta of 4.08 indicates high volatility relative to the market, suggesting a higher risk investment.
• No Dividend Yield reflects the company's focus on reinvesting earnings for growth rather than returning capital to shareholders.

Who Are NOTV's Competitors?

NOTV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NOTV's Key Strengths?

• Comprehensive suite of drug discovery and development services.
• Specialized expertise in preclinical research and analytical instrumentation.
• Established customer relationships with pharmaceutical and medical device companies.
• Proprietary technology in in vivo sampling systems and analytical instruments.

What Are NOTV's Weaknesses?

• Small market capitalization and limited financial resources.
• Negative profit margin and challenges in achieving profitability.
• High beta indicates significant stock price volatility.
• Dependence on the pharmaceutical and medical device industries.

What Could Drive NOTV Stock Higher?

• Potential new partnerships with pharmaceutical and biotech companies to expand service offerings.
• Expansion of service offerings in high-demand areas such as toxicology, bioanalysis, and pharmacology.
• Integration of data analytics and artificial intelligence (AI) into service offerings to enhance efficiency and accuracy.
• Efforts to improve profitability and reduce operating costs.

What Are the Key Risks for NOTV?

• Financial-distress signal — its Altman Z-Score of -1.54 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-74.7%) — the business is not currently generating profit on shareholder capital.
• Intense competition from larger CROs and research product companies could erode market share.
• Stringent regulatory requirements and compliance costs could impact profitability.
• Economic downturns and reduced R&D spending in the pharmaceutical industry could reduce demand for services.
• High beta indicates significant stock price volatility, making it a higher-risk investment.
• Negative profit margin and challenges in achieving profitability pose a significant financial risk.

What Are the Growth Opportunities for NOTV?

• Expansion of Contract Research Services: The global contract research organization (CRO) market is projected to reach $79.5 billion by 2027, growing at a CAGR of 6.8%. Inotiv can capitalize on this growth by expanding its service offerings in high-demand areas such as toxicology, bioanalysis, and pharmacology. Focusing on specialized services and niche markets within the CRO landscape can provide a competitive edge and drive revenue growth over the next 3-5 years.
• Strategic Partnerships and Acquisitions: Forming strategic partnerships with pharmaceutical and biotech companies can provide Inotiv with access to new markets and technologies. Additionally, acquiring complementary businesses can expand its service portfolio and geographic reach. Targeted acquisitions in the CRO and research product sectors can accelerate growth and enhance Inotiv's competitive position within the next 2-3 years.
• Development of Innovative Research Products: Investing in the development of innovative research products, such as advanced in vivo sampling systems and analytical instruments, can create new revenue streams and differentiate Inotiv from its competitors. Focusing on products that address unmet needs in preclinical research can drive adoption and generate recurring revenue through disposables and accessories. Expect to see returns on investment within 3-5 years.
• Geographic Expansion: Expanding operations into new geographic markets, particularly in Asia-Pacific and Europe, can provide Inotiv with access to a larger customer base and diversify its revenue streams. Establishing a presence in key research hubs and partnering with local distributors can facilitate market entry and drive growth over the next 3-5 years. This expansion should be aligned with global pharmaceutical R&D spending trends.
• Leveraging Data Analytics and AI: Integrating data analytics and artificial intelligence (AI) into its service offerings can enhance the efficiency and accuracy of preclinical research. Developing AI-powered tools for data analysis, predictive modeling, and drug discovery can provide Inotiv with a competitive advantage and attract customers seeking advanced research solutions. The timeline for full integration and market impact is estimated at 3-5 years.

What Opportunities Does NOTV Have?

• Expansion of contract research services in high-demand areas.
• Strategic partnerships and acquisitions to expand service portfolio and geographic reach.
• Development of innovative research products to create new revenue streams.
• Geographic expansion into new markets, particularly in Asia-Pacific and Europe.

What Threats Does NOTV Face?

• Intense competition from larger CROs and research product companies.
• Stringent regulatory requirements and compliance costs.
• Economic downturns and reduced R&D spending in the pharmaceutical industry.
• Technological advancements that could render existing products and services obsolete.

What Are NOTV's Competitive Advantages?

• Specialized Expertise: Inotiv possesses specialized expertise in preclinical research and analytical instrumentation.
• Integrated Service Offerings: The company offers a comprehensive suite of services, from drug discovery to regulatory compliance.
• Established Customer Relationships: Inotiv has established long-term relationships with key customers in the pharmaceutical and medical device industries.
• Proprietary Technology: The company develops and markets proprietary in vivo sampling systems and analytical instruments.

What Does NOTV Do?

Inotiv, Inc., founded in 1974 and headquartered in West Lafayette, Indiana, provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries. Originally known as Bioanalytical Systems, Inc., the company rebranded as Inotiv, Inc. in March 2021 to reflect its expanded capabilities and strategic direction. Inotiv operates through two primary segments: Contract Research Services and Research Products. The Contract Research Services segment offers a comprehensive suite of services, including screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing. This segment also provides analytical method development and validation, drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices. Furthermore, it offers in vivo sampling services, stability testing, non-clinical toxicology and pathology services, and climate-controlled archiving services. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, physiology monitoring tools, liquid chromatography and electrochemistry instruments platforms, and analytical products. Inotiv's global presence extends across the United States, North America, the Pacific Rim, and Europe, serving a diverse clientele in the pharmaceutical and research sectors. The company has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program.

What Products and Services Does NOTV Offer?

• Provides screening and pharmacological testing services.
• Offers nonclinical safety testing for pharmaceutical and medical device industries.
• Provides formulation development and regulatory compliance services.
• Conducts quality control testing services.
• Develops and validates analytical methods for drug analysis.
• Offers drug metabolism, bioanalysis, and pharmacokinetics testing.
• Manufactures and markets in vivo sampling systems and accessories.
• Provides climate-controlled archiving services for research data and samples.

How Does NOTV Make Money?

• Generates revenue through contract research services provided to pharmaceutical, chemical, and medical device companies.
• Sells research products, including in vivo sampling systems and analytical instruments.
• Offers a comprehensive suite of services spanning drug discovery and development.
• Operates through two segments: Contract Research Services and Research Products.

What Industry Does NOTV Operate In?

Inotiv operates within the medical diagnostics and research industry, a sector characterized by continuous innovation and stringent regulatory requirements. The global market for contract research services is experiencing steady growth, driven by the increasing complexity of drug development and the pharmaceutical industry's reliance on outsourcing. The competitive landscape includes larger CROs (Contract Research Organizations) and specialized research product companies. Inotiv differentiates itself through its integrated service offerings, combining contract research with the development and sale of analytical instruments. This positions the company to capture a broader share of the preclinical research market.

Who Are NOTV's Key Customers?

• Pharmaceutical companies seeking drug discovery and development services.
• Chemical companies requiring safety testing and analysis.
• Medical device companies needing regulatory compliance and quality control testing.
• Contract research organizations (CROs) requiring specialized research products and services.

ROE -75%Key Financial Metrics

Return on equity for Inotiv, Inc. stands at -74.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -12.4%, showing how much profit it generates from its asset base. A current ratio of 0.27 means current liabilities exceed short-term assets, a liquidity point worth watching.

How Inotiv, Inc. Is Valued

Inotiv, Inc. carries a market capitalization of $2.79M, placing it in the micro-cap category. Relative to its peer group, NOTV's quantitative score of 40/100 is below the peer average of 60/100.

F-Score 4/9Financial Health

Inotiv, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -1.54 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Inotiv, Inc. revenue of about $529.5M for fiscal 2026, with EPS near $-2.27.

NOTV Financials

NOTV Latest News

NOTV Analyst Consensus

NOTV MoonshotScore

What Investors Ask About Inotiv, Inc. (NOTV) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources